Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Contineum Therapeutics (CTNM) Invested Capital (2023 - 2025)

Contineum Therapeutics has reported Invested Capital over the past 3 years, most recently at $180.5 million for Q3 2025.

  • Quarterly results put Invested Capital at $180.5 million for Q3 2025, down 14.16% from a year ago — trailing twelve months through Sep 2025 was $180.5 million (down 14.16% YoY), and the annual figure for FY2024 was $198.1 million, up 391.55%.
  • Invested Capital for Q3 2025 was $180.5 million at Contineum Therapeutics, up from $171.4 million in the prior quarter.
  • Over the last five years, Invested Capital for CTNM hit a ceiling of $217.5 million in Q2 2024 and a floor of -$97.5 million in Q1 2023.
  • Median Invested Capital over the past 3 years was $171.4 million (2025), compared with a mean of $73.2 million.
  • Biggest five-year swings in Invested Capital: surged 492.38% in 2024 and later decreased 21.2% in 2025.
  • Contineum Therapeutics' Invested Capital stood at -$67.9 million in 2023, then soared by 391.55% to $198.1 million in 2024, then dropped by 8.88% to $180.5 million in 2025.
  • The last three reported values for Invested Capital were $180.5 million (Q3 2025), $171.4 million (Q2 2025), and $184.8 million (Q1 2025) per Business Quant data.